Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Conditions:   Rectal Adenocarcinoma;   Circulating Tumor DNA;   Minimal Residual Disease;   Neoadjuvant Chemoradiotherapy Intervention:   Diagnostic Test: MRD detection Sponsors:   WeiWei Xiao;   Haplox Biotechnology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials